Kemocarb 150mg Injection

Single Agent Therapy Carboplatin Injection, as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m 2 IV on day 1 every 4 weeks (alternatively see Formula Dosing ). Combination Therapy with Cyclophosphamide In the chemotherapy of advanced ovarian cancer, an effective combination for previously untreated patients consists of: Carboplatin Injection - 300 mg/m 2 IV on day 1 every four weeks for six cycles (alternatively see Formula Dosing ). Cyclophosphamide - 600 mg/m 2 IV on day 1 every four weeks for six cycles.

Directions from the U.S. FDA-approved label for Carboplatin — your doctor or pharmacist may advise differently.

Carboplatin Injection is contraindicated in patients with a history of severe allergic reactions to cisplatin or other platinum-containing compounds. Carboplatin Injection should not be employed in patients with severe bone marrow depression or significant bleeding.

Excerpt from the U.S. FDA-approved label for Carboplatin. Talk to a pharmacist or doctor before use.

Bone marrow suppression (leukopenia, neutropenia, and thrombocytopenia) is dose-dependent and is also the dose-limiting toxicity. Peripheral blood counts should be frequently monitored during carboplatin treatment and, when appropriate, until recovery is achieved. Median nadir occurs at day 21 in patients receiving single agent carboplatin. In general, single intermittent courses of carboplatin should not be repeated until leukocyte, neutrophil, and platelet counts have recovered.

Warnings and precautions excerpt from the U.S. FDA-approved label for Carboplatin — not a complete list. Talk to a pharmacist or doctor before use.

For a comparison of toxicities when carboplatin or cisplatin was given in combination with cyclophosphamide, see CLINICAL STUDIES: Use with Cyclophosphamide for Initial Treatment of Ovarian Cancer: Comparative Toxicity.

Excerpt from the U.S. FDA-approved label for Carboplatin — not a complete list. Talk to a pharmacist or doctor about side effects.

8 brands · 4 makers in the NepalDoc catalog — see the full Carboplatin guide →

Unopened vials of Carboplatin Injection are stable to the date indicated on the package when stored at 25°C (77°F); excursions permitted from 15°–30°C (59°–86°F). Protect from light. Carboplatin Injection multiple-dose vials maintain microbial, chemical, and physical stability for up to 14 days at 25°C following multiple needle entries.

Storage information from the U.S. FDA-approved label for Carboplatin.